Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 15.72
+1.83 (13.17%)
Jun 18, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Nanjing Vazyme Biotech stock have an average target of ¥19.59, which predicts a 24.62% increase from the current stock price of 15.72.
Price Target: ¥19.59 (+24.62%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Nanjing Vazyme Biotech stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | Sep '25 | Nov '25 | Dec '25 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 2 | 3 |
Financial Forecast
Revenue This Year
1.60B
from 1.38B
Increased by 16.05%
Revenue Next Year
1.88B
from 1.60B
Increased by 17.37%
EPS This Year
0.32
from -0.15
EPS Next Year
0.37
from 0.32
Increased by 17.07%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.6B | ||
| Avg | 1.6B | ||
| Low | 1.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.2% | ||
| Avg | 16.0% | ||
| Low | 15.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.32 | ||
| Avg | 0.32 | ||
| Low | 0.32 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |